Hyperuricemia as a trigger of immune response in hypertension and chronic kidney disease.
Level 5 - mechanism / opinion, no new human data
Narrative review describing mechanistic models without new empirical human data
PubMed 32650020 · doi:10.1016/j.kint.2020.05.056
What was done
This is a narrative review describing a proposed mechanistic model of how asymptomatic hyperuricemia contributes to hypertension and chronic kidney disease through hemodynamic alterations and innate and adaptive immune activation.
What was found
No numerical data or effect sizes are reported in the abstract. The abstract details a two-hit model: an initial phase of renin-angiotensin activation and nitric oxide synthesis inhibition causing endothelial dysfunction and sodium reabsorption, followed by immune activation where uric acid acts as a danger molecule triggering pattern-recognition receptors, dendritic cells, T cells, and inflammasome cytokine secretion. The authors note that despite this mechanistic rationale, robust clinical evidence that lowering uric acid slows renal disease progression is lacking.
Why it matters
The paper synthesizes how hyperuricemia functions as an immune and inflammatory trigger in cardiorenal pathology, while clarifying the discrepancy between preclinical mechanistic rationale and current clinical trial evidence for urate-lowering therapy in chronic kidney disease.
Limits
This is a narrative review presenting mechanistic theory without primary human data, quantitative synthesis, or systematic search methodology in the abstract. Clinical therapeutic implications remain unproven due to a lack of robust trial evidence.
Cited by
- supports Elevated uric acid causes hypertension by inhibiting endothelial nitric oxide production.